2026-08-29T10:01:31Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/82602025-04-10T12:49:53Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Mellado, Emilia author Garcia-Effron, Guillermo author Alcazar-Fuoli, Laura author Cuenca-Estrella, Manuel author Rodriguez-Tudela, Juan Luis author 2004-07 Five clinical isolates of Aspergillus fumigatus that exhibited similar patterns of reduced susceptibility to itraconazole and other triazole drugs were analyzed. Sequence analysis of genes (cyp51A and cyp51B) encoding the 14alpha-sterol demethylases revealed that all five strains harbored mutations in cyp51A resulting in the replacement of methionine at residue 220 by valine, lysine, or threonine. When the mutated cyp51A genes were introduced into an A. fumigatus wild-type strain, the transformants exhibited reduced susceptibility to all triazole agents, confirming that the mutations were responsible for the resistance phenotype. Antimicrob Agents Chemother. 2004 Jul;48(7):2747-50. 10.1128/AAC.48.7.2747-2750.2004 0066-4804 Antimicrobial agents and chemotherapy 15215142 http://hdl.handle.net/20.500.12105/8260 Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs